Black Rock Inc. Aravive, Inc. Transaction History

Black Rock Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.11 - $0.22 $279 - $558	-2,539 Reduced 0.8%	315,179 $37,000
Q3 2023 Nov 13, 2023	SELL	$0.11 - $1.76 $349 - $5,595	-3,179 Reduced 0.99%	317,718 $41,000
Q2 2023 Aug 11, 2023	BUY	$1.25 - $1.92 $140,336 - $215,556	112,269 Added 53.81%	320,897 $404,000
Q1 2023 May 12, 2023	BUY	$1.29 - $2.46 $37,100 - $70,749	28,760 Added 15.99%	208,628 $417,000
Q4 2022 Feb 13, 2023	BUY	$1.2 - $1.83 $1,228 - $1,873	1,024 Added 0.57%	179,868 $237,000
Q3 2022 Nov 14, 2022	SELL	$0.61 - $1.03 $6,589 - $11,126	-10,802 Reduced 5.7%	178,844 $146,000
Q2 2022 Aug 12, 2022	BUY	$0.93 - $1.9 $15,756 - $32,191	16,943 Added 9.81%	189,646 $187,000
Q1 2022 May 12, 2022	SELL	$1.85 - $2.75 $3,463 - $5,148	-1,872 Reduced 1.07%	172,703 $333,000
Q4 2021 Feb 10, 2022	BUY	$2.19 - $4.07 $3,698 - $6,874	1,689 Added 0.98%	174,575 $382,000
Q3 2021 Nov 09, 2021	SELL	$3.67 - $5.8 $13,920 - $21,999	-3,793 Reduced 2.15%	172,886 $644,000
Q2 2021 Aug 11, 2021	BUY	$4.65 - $6.42 $821,557 - $1.13 Million	176,679 New	176,679 $1.06 Million

28.1K

Ticker ARAV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,518,300
Description
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.